# Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

> **NCT07659574** · PHASE3 · RECRUITING · sponsor: **The United Bio-Technology (Hengqin) Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** UBT251 Injection 2.0 mg
- **DRUG:** UBT251 Injection 4.0 mg
- **DRUG:** UBT251 Injection 6.0 mg
- **DRUG:** UBT251 Injection Placebo 2.0 mg
- **DRUG:** UBT251 Injection Placebo 4.0 mg
- **DRUG:** UBT251 Injection Placebo 6.0 mg

## Key facts

- **NCT ID:** NCT07659574
- **Lead sponsor:** The United Bio-Technology (Hengqin) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-07
- **Primary completion:** 2027-09-24
- **Final completion:** 2027-10-22
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07659574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07659574, "Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07659574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*